No profile data available.
Allogene Therapeutics, Inc. (ALLO) is a healthcare company in the additional cancer treatment drugs industry, based in South San Francisco, United States, with about 150 full-time employees.
It reported revenue of $0 for fiscal year 2025, down 100.0% from fiscal year 2024, and net income of -$190.89 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $4.64 million. Its market capitalization was $504.42 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Allogene Therapeutics reported $0 in revenue for fiscal year 2025, down 100.0% from $22,000 in fiscal year 2024. In Q2 2026 revenue was $4.64 million.
$504.42 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Aura Biosciences, Inc. (AURA), CytomX Therapeutics, Inc. (CTMX), Crescent Biopharma, Inc. (CBIO), Arvinas, Inc. (ARVN).